Home/Filings/4/0001126234-23-000018
4//SEC Filing

Schuchart Aaron 4

Accession 0001126234-23-000018

CIK 0001126234other

Filed

Feb 2, 7:00 PM ET

Accepted

Feb 3, 5:04 PM ET

Size

11.3 KB

Accession

0001126234-23-000018

Insider Transaction Report

Form 4
Period: 2023-02-01
Schuchart Aaron
Chief Business Officer
Transactions
  • Award

    Common Stock

    2023-02-01$3.52/sh+1,000$3,5205,485 total
  • Tax Payment

    Common Stock

    2023-02-01$3.52/sh104$3665,381 total
  • Award

    Stock Option (Right to Buy)

    2023-02-01+12,00012,000 total
    Exercise: $3.52Common Stock (12,000 underlying)
Footnotes (8)
  • [F1]Represents shares issued as restricted stock units ("RSUs") under the Issuer's 2009 Equity Incentive Plan, as amended, (the "Plan") that were received as an award, for no consideration. The RSUs vest in a series of four successive annual installments beginning on February 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
  • [F2]Includes 348 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of two successive annual installments with the next installment occurring on February 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
  • [F3]Includes 750 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of three successive annual installments with the next installment occurring on February 1, 2024, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
  • [F4]Includes 500 shares acquired under the Lumos Pharma, Inc. 2010 Employee Stock Purchase Plan on December 31, 2022.
  • [F5]Represents shares of Common Stock withheld by the Issuer in satisfaction of its tax withholding obligation with respect to the vesting of 424 previously reported restricted stock units ("RSUs") granted to the Reporting Person.
  • [F6]Grant to the Reporting Person of a stock option under the Plan. 50% of the option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on March 1, 2023, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the Date of Grant.
  • [F7]The remaining 50% of the stock options vest and become exercisable in 3 substantially equal tranches on the first of the month following an increase of closing stock price, as defined as the closing stock price on Nasdaq Stock Market by at least 50%, 100% and 150%, respectively, above the closing stock on December 31, 2022, when measured over 30 consecutive calendar days, provided such increase occurs within two years of the Date of Grant, otherwise such options shall be cancelled.
  • [F8]Unless otherwise disclosed, the option expires ten years after the date of grant.

Issuer

LUMOS PHARMA, INC.

CIK 0001126234

Entity typeother

Related Parties

1
  • filerCIK 0001709258

Filing Metadata

Form type
4
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 5:04 PM ET
Size
11.3 KB